VolitionRX Ltd
VNRX0.680USD
+0.056+8.96%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
70.71MValor de mercado
PerdaP/L TTM
Mais detalhes de VolitionRX Ltd Empresa
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Informações da empresa
Código da empresaVNRX
Nome da EmpresaVolitionRX Ltd
Data de listagemFeb 06, 2015
CEODr. Jasmine Kway
Número de funcionários85
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço1489 West Warm Springs Road
CidadeHENDERSON
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal89014
Telefone17024251561
Sitehttps://volition.com/
Código da empresaVNRX
Data de listagemFeb 06, 2015
CEODr. Jasmine Kway
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.88M
+2.78%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.18M
+0.69%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
388.15K
+7.22%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
341.11K
+8.80%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
203.61K
+6.54%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
203.55K
-10.28%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
166.43K
+4.37%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
164.38K
+13.52%
Dr. Andrew Retter
Dr. Andrew Retter
Chief Medical Officer
Chief Medical Officer
151.16K
+9.71%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.88M
+2.78%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.18M
+0.69%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
388.15K
+7.22%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
341.11K
+8.80%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
203.61K
+6.54%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cotterford Co., Ltd.
11.16%
Lagoda Investment Management, L.P.
10.88%
Armistice Capital LLC
7.89%
Innes (Guy Archibald)
2.68%
Reynolds (Cameron John)
2.02%
Outro
65.37%
Investidores
Investidores
Proporção
Cotterford Co., Ltd.
11.16%
Lagoda Investment Management, L.P.
10.88%
Armistice Capital LLC
7.89%
Innes (Guy Archibald)
2.68%
Reynolds (Cameron John)
2.02%
Outro
65.37%
Tipos de investidores
Investidores
Proporção
Investment Advisor
13.11%
Corporation
12.09%
Hedge Fund
8.10%
Individual Investor
7.33%
Investment Advisor/Hedge Fund
1.04%
Research Firm
0.04%
Outro
58.29%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
78
41.39M
40.30%
+860.69K
2025Q1
83
44.42M
46.85%
+2.70M
2024Q4
82
41.53M
44.82%
+1.50M
2024Q3
82
38.59M
41.90%
+9.42M
2024Q2
82
28.77M
32.86%
+105.49K
2024Q1
84
28.22M
34.52%
+1.47M
2023Q4
87
26.17M
37.10%
+183.39K
2023Q3
91
25.37M
36.48%
-477.38K
2023Q2
98
25.03M
37.36%
-1.92M
2023Q1
127
25.94M
45.68%
-639.07K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cotterford Co., Ltd.
12.01M
11.65%
--
--
Apr 25, 2025
Lagoda Investment Management, L.P.
10.19M
9.89%
+2.62M
+34.56%
Mar 31, 2025
Armistice Capital LLC
8.21M
7.97%
-275.46K
-3.25%
Mar 31, 2025
Innes (Guy Archibald)
2.81M
2.72%
+20.00K
+0.72%
Jun 03, 2025
Reynolds (Cameron John)
1.88M
1.83%
+12.50K
+0.67%
Jun 12, 2025
The Vanguard Group, Inc.
706.06K
0.69%
+69.39K
+10.90%
Mar 31, 2025
Concord International Inc.
1.01M
0.98%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
761.95K
0.74%
+18.11K
+2.43%
Mar 31, 2025
Micallef (Jacob Vincent)
456.18K
0.44%
-21.53K
-4.51%
Jun 01, 2025
BlackRock Institutional Trust Company, N.A.
445.19K
0.43%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
